Clinical Trial: Efficacy and Safety of SHR-A1811 Followed by Dalpiciclib and Endocrine Therapy in HR+/HER2-Low/Ultra-Low Advanced Breast Cancer

U.S., June 26 -- ClinicalTrials.gov registry received information related to the study (NCT07037199) titled 'Efficacy and Safety of SHR-A1811 Followed by Dalpiciclib and Endocrine Therapy in HR+/HER2-Low/Ultra-Low Advanced Breast Cancer' on June 13.

Brief Summary: This multicenter, prospective phase II clinical trial evaluates the efficacy and safety of sequential SHR-A1811 followed by dalpiciclib plus endocrine therapy (fulvestrant or aromatase inhibitors) in 45 patients with HR+/HER2-low/ultra-low advanced breast cancer. Enrolled patients will receive SHR-A1811 monotherapy for 6-8 cycles until clinical benefit, then transition to dalpiciclib with endocrine therapy until disease progression or unacceptable toxicity. The primary endpoint i...